Skip to main content
. 2020 Jun 1;12(6):1444. doi: 10.3390/cancers12061444

Figure 2.

Figure 2

A CONSORT diagram before and after random assignment of the APL204 study. Numbers in parentheses refer to the numbers of patients. ATRA, all-trans retinoic acid; DNR, daunorubicin; IDA, idarubicin; MIT, mitoxantrone; AraC, cytarabine; CR, complete remission.